الصفحة الرئيسية>>Lipids>> P450>>(±)12(13)-EpOME-d4

(±)12(13)-EpOME-d4 (Synonyms: (±)12,13-EODE-d4, Isoleukotoxin-d4, (±)Vernolic Acidd4)

رقم الكتالوجGC46257

A neuropeptide with diverse biological activities

Products are for research use only. Not for human use. We do not sell to patients.

(±)12(13)-EpOME-d4 التركيب الكيميائي

Cas No.: N/A

الحجم السعر المخزون الكميّة
25 μg
155٫00
متوفر
50 μg
294٫00
متوفر
100 μg
555٫00
متوفر
250 μg
1234٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

(±)12(13)-EpOME-d4 is intended for use as an internal standard for the quantification of (±)12(13)-EpOME by GC- or LC-MS. (±)12(13)-EpOME is the 12,13-cis epoxide form of linoleic acid .1,2 It is formed primarily via linoleic acid metabolism by the cytochrome P450 (CYP) isoforms CYP2J2, CYP2C8, and CYP2C9, however, CYP1A1 can contribute to (±)12(13)-EpOME production when pharmacologically induced.2 (±)12(13)-EpOME (500 µM) induces mitochondrial dysfunction and cell death in renal proximal tubule epithelial cells.

1.Hayakawa, M., Sugiyama, S., Takamura, T., et al.Neutrophils biosynthesize leukotoxin, 9,10-epoxy-12-octadecenoateBiochem. Biophys. Res. Commun.137(1)424-430(1986) 2.Hildreth, K., Kodani, S.D., Hammock, B.D., et al.Cytochrome P450-derived linoleic acid metabolites EpOMEs and DiHOMEs: A review of recent studiesJ. Nutr. Biochem.19108484(2020)

مراجعات

Review for (±)12(13)-EpOME-d4

Average Rating: 5 ★★★★★ (Based on Reviews and 34 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for (±)12(13)-EpOME-d4

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.